Abstract
Introduction
Observational and experimental studies of patients on oral anticoagulation therapy show annual fatal bleeding rates of up to 4.8% and major nonfatal bleeding rates of 2.4% to 8.1%. 1 Although newer oral anticoagulant direct thrombin inhibitor agents are available, their high cost and uncertain safety profile will limit their use in the short-term. 2, 3 Careful control of warfarin is critical to prevent bleeding and thromboembolic complications. There is evidence that the number of complications increases in parallel with the time patients spend outside target therapeutic International Normalised Ratio (INR) range. 4, 5 Extreme INRs increase the risk of adverse events. 6 In one study, the risk of bleeding at an INR over 7 was 40 times the risk at an INR in the low therapeutic range (2-2.9) and 20 times the risk at an INR in the high therapeutic range (3-4.4). 6 Higher variability of the INR in patients with mechanical heart valves is associated with shorter survival. 7 Patient self-management (PSM) of warfarin may improve anticoagulation control and thereby reduce adverse events through convenient, frequent INR testing. The CoaguChek coagulometer, a self-testing device, has been shown to be accurate and reliable in experimental and clinical studies. 8, 9 PSM varies in scope from calling an anticoagulation clinic to confirm a dose, to total independent management by the patient after one or more teaching sessions. Dosing algorithms have occasionally been used in trials of PSM where INR has been stabilised already, with good results. 10, 11 Evidence from European trials seems to support PSM as a method to improve anticoagulation management outcomes, but many randomised studies to date have been biased or small.
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This large study with an unbiased design with regard to evaluation of outcome INRs investigated whether PSM is non-inferior or superior to usual warfarin management.
PSM using the CoaguChek device and a dosing algorithm was compared to usual care
by determining the proportion of blinded outcome INRs in the target range. The hypothesis test was that the proportion of out-of-range INRs in the PSM group would be 6% less than in the usual care group.
Methods

Study design
The study used a randomised controlled trial design to compare 1. standard management of warfarin control (usual care) using local laboratory testing and dose scheduling by a general practitioner, cardiologist or coagulation clinic with 2. use of an INR home self-testing device combined with dosing scheduled via a validated home individualised algorithm (PSM). Study staff and trial patients were blinded to assessment of the primary outcome. coagulation disorder, underlying liver disease, a condition limiting their ability to comply with the study routine such as drug or alcohol addiction, a visual deficit, or tremor or tactile dysfunction; or if they failed a mini-mental state evaluation (score <8 out of 10). They were also excluded if they were unable to comply with monthly laboratory INR tests with blood transportable to the central study laboratory.
Patient population
All patients gave written informed consent. The study protocol was approved by local and national ethics committees and was undertaken in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines (ACTRN12606000019505).
Study intervention and randomisation
All patients received a 60-minute training session in the therapeutic use of warfarin.
Eligible patients were randomly allocated to ongoing usual care or PSM for 12 months using a central phone-based randomisation system at the NHMRC Clinical Trials Centre. The randomisation method was minimisation, with stratification for age (≤65, >65), sex, duration of prior warfarin therapy (3-6 months, >6 months), current midpoint of INR range (<2.5, 2.5-2.9, >3.0), indication for warfarin (chronic atrial fibrillation, a mechanical heart valve, 2 or more mechanical heart valves) and type of management (general practitioner, cardiologist, clinic) before enrolment into the study.
Study coordinators notified patients of their study group allocation as blinding was The algorithm was validated against records of patients by ensuring dose changes using the algorithm were negligible compared to typically prescribed doses. result, and the dose they were instructed to take. This process was intended to match levels of involvement in individual data tracking in the two groups as far as possible. 
Study outcomes
Statistical analysis
The study was designed to detect a 10% difference between assigned groups in the proportion of INR readings outside the therapeutic range. A sample size of 310 patients was expected to offer at least 80% power, with a two-sided alpha, with 95% confidence, to detect such a difference, allowing for up to 10% drop-ins to PSM in some form, and up to 10% dropouts from PSM. The investigators considered it reasonable to miss a 20% effect because of the number of smaller studies and the high number of patients that would have been required to obtain 90% power. During the study, the blinded Steering Committee determined that a non-inferior outcome for PSM would be meaningful owing to the convenience afforded by home testing, provided that the PSM strategy proved safe. Consequently, the planned study analysis was modified to a closed testing procedure, first of non-inferiority with a pre specified
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margin of 6% in rate of out-of-range values followed by superiority testing if noninferiority was satisfied. The margin of 6% was empirically based on the maximum plausible risk of detriment that would not outweigh the added convenience of home testing and dosing with PSM.
The primary test for comparison was the two-sample t test. The primary endpoint data was normally distributed along with the other continuous endpoints and thus parametric tests could be used.
A secondary analysis used generalised estimating equations, with a compound symmetric correlation structure and a logistic link, to account for the repeated measures for each patient. Statistical inferences were drawn for a two-sided P value of less than 5%. All analyses were unadjusted and based on the intention-to-treat principle.
Results
Screening and baseline characteristics
Of 1722 subjects screened for the trial, 310 were eligible and consented to be randomised ( Figure 2 ). The treatment groups were generally well-balanced with respect to baseline and anticoagulation characteristics, including the span of the prescribed INR range (Table 1) . Compliance with trial participation was generally good, with only 11 (7%) subjects allocated to PSM withdrawing during the treatment period and 24 (15%) allocated to usual care withdrawing from monthly provision of central-outcome blood samples at some time during the 12-month follow-up period.
Patients who withdrew from the PSM group were managed by their usual practitioner.
One subject was lost to follow-up (usual care group). The mean number of outcome
INRs captured was 10.1 out of a possible 12. All patients were analysed for the primary outcome.
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The mean number of blinded outcome INRs obtained, the mean value of the blinded outcome INRs, and the mean warfarin dose taken did not appear to differ between groups ( Table 2) . The primary endpoint, the proportion of out-of-range INRs, was non-significantly lower for the PSM-allocated group (40.7% usual care versus 35.5% PSM), just failing to reach significance for superiority (P=0.08), but being highly significant for non-inferiority, with the one-sided 95% confidence interval being much greater than -6% (at +5.2%, P<0.001).
Self-managed patients also had significantly fewer extreme INR readings (P=0.03) and a smaller average deviation over all readings from the centre of their individual target INR ranges than the usual-care patients (difference = 0.04; 95% CI, 0.01-0.09,
P=0.02).
No significant differences were seen between treatment groups for the proportion of subjects with at least one reading in an extreme range at any time. There is evidence that the time to the first extreme reading was 46% longer among those allocated to the PSM group (95% CI, 20%-103%, P=0.05; Figure 3 ).
There was no difference in the rate of serious adverse events (Table 3) . Irrespective of treatment allocation, there were more than twice as many bleeding as thrombotic events. The only death, of a patient with pulmonary hypertension and severe cardiac dysfunction who died from recurrent intracerebral haemorrhage, was arbitrated by the ISDMC to be due to warfarin therapy (but not in the extreme range) and not related to the study protocol.
Discussion
Summary of findings
Frequent INR testing combined with a warfarin management algorithm for selfmanagement is as good as usual care, and superior to usual care in some aspects of 
Possible study limitations explained
The eligibility criteria were designed to be minimally restrictive. There was no requirement as to education level or age. No patient was excluded based on the minimental exam. Almost 40% of patients were aged over 65 years, and 25% were over 70 years, indicating a balance of young and old patients who were able to use the test device and dosing self-management algorithm.
A single laboratory network was used to ensure consistency of quality control procedures for outcome INR measurement. Of the 1722 screened patients, 356
(20.7%) were ineligible because they lived too far from a pathology laboratory thereby limiting the trial to patients in the city areas. In real practice rural patients could self-manage warfarin. Self management would facilitate in-range INRs compared to usual care in rural areas because testing and general practitioner management (usual care) are likely to be less accessible in rural than urban areas.
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Of all patients screened for the study, 27.4% declined to participate, largely because of a preference for usual care and the difficulty in attending the single laboratory for Greater INR variability may result from usual care patients managed mostly by general practitioners rather than anticoagulation clinic specialists. 12 Here, INR results were determined by a central laboratory blinded to treatment, which eliminated bias in terms of the outcome INR.
INR measurement device and primary endpoint
In a study comparing the CoaguChek S and XS with plasma INR testing, the device had good correlation with lab measurement (r 2 of 0.9). 13 
Correlation decreased at
Warfarin SMART The proportion of out of range INRs reported in other studies is 21% to 51%, the results of this study being consistent with those studies.
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Significance and strengths of this study 
Consistency with other studies
Of the 11 randomised trials included in the recent Cochrane review of warfarin selfmanagement, only three used central blinded outcome INR tests, and all were smaller than our study. 17 Two (n=50, n=100) were unable to show a difference in outcome INR measurements with PSM. 18, 19 The third, a well-designed, unbiased but smaller trial (n=179), showed a higher proportion of INRs in target range for PSM than usual care.
22
The present, larger study adds weight to that study by proving non-inferiority of PSM.
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Limitations of other large studies on out-of-range INRs
The Early Self-Controlled Anticoagulation Trial (ESCAT) series of studies on PSM,
were large and showed that PSM was associated with a greater time within the therapeutic INR range, and a decreased rate of thromboembolism and bleeding events 23 . However, these studies have been criticised 12 because there was more frequent testing in the PSM group, and follow-up studies included additional patients and a different primary endpoint (long-term survival) 24 .
A large, randomised trial of PSM, by Menéndez-Jándula et al. 23 , showed improved time in range but was limited by testing up to 6 times as frequently in the PSM group.
Another large (n=617) randomised controlled trial was unable to show a difference in time in range between PSM and conventional management. 24 Two large meta-analyses of time in therapeutic INR range favoured PSM or patient self-testing, but again did not analyse equivalent numbers of INR measurements in each group, thereby potentially introducing bias.
12, 25
Significance of randomised trials and meta-analyses with serious adverse events as an outcome measure
Because of the paucity of high-quality, randomised trials, PSM has not been shown to reduce serious adverse events other than in a selected population of elderly patients. 26 This positive result may have been due to the high rate of haemorrhage in those over 70 years of age. 27 Another recent randomised study of PST pre-specified subgroup analysis showed a reduction in events in the PSM group but the self-testing individuals were not significantly different from the control group.
This adds evidence to the positive impact of PSM on adverse events.
A meta-analysis of 22 randomised trials with PST or PSM, 5 of which were considered high quality, showed an improvement in thromboembolic complications and death. 30 In another meta-analysis of 10 randomised trials of PSM, there was a reduction in death and major complications when PSM was used. 25 Only 2 of the trials were considered to be high quality and the positive effect of PSM on risk of death was not evident in these two trials. The effect of PSM, therefore, needs to be clearly delineated from PST alone when designing meta-analyses and randomised trials about the clinical outcomes of warfarin therapy.
Conclusions
The Warfarin SMART study, the largest of its kind with an unbiased design of A large, definitive randomised trial of PSM is required to determine the effect on clinical outcomes.
Legends
Figure 1
Sample algorithm for a patient using the ColourChart
Figure 2
Flow chart for SMART study
Figure 3
Proportion of patients over time with at least one INR reading in an extreme range (high ≥4.5; low <1.5). Log-rank P=0.05.
Figure 4
More frequent testing of the INR can lead to higher proportion of tests being out of range despite the same number of INR spikes out of range.
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